Bate Roger, Tren Richard, Hess Kimberly, Attaran Amir
Africa Fighting Malaria, Washington, D.C., USA.
Malar J. 2009 Feb 25;8:33. doi: 10.1186/1475-2875-8-33.
New artemisinin combination therapies pose difficulties of implementation in developing and tropical settings because they have a short shelf-life (two years) relative to the medicines they replace. This limits the reliability and cost of treatment, and the acceptability of this treatment to health care workers. A multi-pronged investigation was made into the chemical and physical stability of fixed dose combination artemether-lumefantrine (FDC-ALU) stored under heterogeneous, uncontrolled African conditions, to probe if a shelf-life extension might be possible.
Seventy samples of expired FDC-ALU were collected from private pharmacies and malaria researchers in seven African countries. The samples were subjected to thin-layer chromatography (TLC), disintegration testing, and near infrared Raman spectrometry for ascertainment of active ingredients, tablet integrity, and chemical degradation of the tablet formulation including both active ingredients and excipients.
Seventy samples of FDC-ALU were tested in July 2008, between one and 58 months post-expiry. 68 of 70 (97%) samples passed TLC, disintegration and Raman spectrometry testing, including eight samples that were post-expiry by 20 months or longer. A weak linear association (R2 = 0.33) was observed between the age of samples and their state of degradation relative to brand-identical samples on Raman spectrometry. Sixty-eight samples were retested in February 2009 using Raman spectrometry, between eight and 65 months post-expiry. 66 of 68 (97%) samples passed Raman spectrometry retesting. An unexpected observation about African drug logistics was made in three batches of FDC-ALU, which had been sold into the public sector at concessional pricing in accordance with a World Health Organization (WHO) agreement, and which were illegally diverted to the private sector where they were sold for profit.
The data indicate that FDC-ALU is chemically and physically stable well beyond its stated shelf-life in uncontrolled, tropical conditions. While these data are not themselves sufficient, it is strongly suggested that a re-evaluation of the two-year shelf-life by drug regulatory authorities is warranted.
新型青蒿素联合疗法在发展中及热带地区的实施存在困难,因为相对于它们所替代的药物,其保质期较短(两年)。这限制了治疗的可靠性和成本,以及医护人员对这种治疗方法的接受程度。针对在非洲非均匀、不受控条件下储存的固定剂量复方蒿甲醚-本芴醇(FDC-ALU)的化学和物理稳定性进行了多方面调查,以探究是否有可能延长保质期。
从七个非洲国家的私人药店和疟疾研究人员处收集了70份过期的FDC-ALU样本。对这些样本进行薄层色谱法(TLC)、崩解测试和近红外拉曼光谱分析,以确定活性成分、片剂完整性以及片剂配方(包括活性成分和辅料)的化学降解情况。
2008年7月对70份FDC-ALU样本进行了测试,这些样本过期时间在1至58个月之间。70份样本中的68份(97%)通过了TLC、崩解和拉曼光谱测试,其中包括8份过期20个月或更长时间的样本。在拉曼光谱分析中,观察到样本的保存时间与其相对于品牌相同样本的降解状态之间存在微弱的线性关联(R2 = 0.33)。2009年2月,对68份样本在过期8至65个月之间再次使用拉曼光谱进行测试。68份样本中的66份(97%)通过了拉曼光谱复测。在三批FDC-ALU中发现了一个有关非洲药品物流的意外情况,这些药品根据世界卫生组织(WHO)的协议以优惠价格出售给公共部门,但被非法转移到私营部门并被用于牟利。
数据表明,在不受控的热带条件下,FDC-ALU在化学和物理性质上的稳定性远远超过其规定的保质期。虽然这些数据本身并不充分,但强烈建议药品监管当局对两年的保质期进行重新评估。